secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310588
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta grants CEO Ingram $12M equity awards after 8-year gap
-------------------------------------------------------------

- CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.
- Performance awards can pay out 0-200% of target; vesting subject to 3-year service period from Dec 7, 2025.
- First equity grant for Ingram since 2017; previously deferred consistent with employment agreement.
- Performance condition based on cumulative Incentive EBITDA over two-year period ending Dec 31, 2027.
- Up to 269,542 shares at target across four award types (RSUs, units, restricted shares, performance shares).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312525310588/0001193125-25-310588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312525310588/d15497d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer